The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial
Abstract
Previous studies have demonstrated that delivery of a recombinant adeno-associated virus (AAV) vector encoding the complete human cystic fibrosis transmembrane regulator (CFTR) cDNA (tgAAVCF) to the nose, sinus, and lungs of subjects with cystic fibrosis (CF) was safe and well tolerated. In a small randomized, double-blind study of three doses of aerosolized tgAAVCF or placebo at 30-day intervals, encouraging but non-significant trends in pulmonary function and induced sputum interleukin 8 (IL-8) levels were seen at early time points. This larger study was conducted to verify these trends. One hundred and two subjects aged 12 years and older with mild-to-moderate cystic fibrosis (forced expiratory flow in 1 sec [FEV1]:60% predicted) were randomized to two aerosolized doses of 1x10(13)DNase-resistant particles of tgAAVCF (n=51) or matching placebo (n=51) administered 30 days apart. Although tgAAVCF was well tolerated, the study did not meet its primary efficacy end point of statistically significant improvement in FEV1 30 days after initial administration of tgAAVCF compared with placebo. There were no significant differences in spirometric lung function over time, induced sputum biologic markers, or days of antibiotic use in either treatment group. Thus repeated doses of aerosolized tgAAVCF were safe and well tolerated, but did not result in significant improvement in lung function over time. Because gene transfer is the simplest, most basic way to correct the underlying genetic defect that leads to disease in CF, further research is warranted to develop an effective gene transfer agent for the treatment of CF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Webb, A. K. (2006) · Cited by 4,369
Fuchs, H. J., Borowitz, D. S., Christiansen, D. H., Morris, E. M., Nash, M. L., Ramsey, B. W., Rosenstein, B. J., Smith, A. L., & Wohl, M. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409083311003 · Cited by 1,539
Self-citationIntermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,300
Self-citationFlotte, T. R., Afione, S. A., Conrad, C., McGrath, S. A., Solow, R., Oka, H., Zeitlin, P. L., Guggino, W. B., & Carter, B. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10613 · Cited by 490
Self-citationEgan, M., Flotte, T., Afione, S., Solow, R., Zeitlin, P. L., Carter, B. J., & Guggino, W. B. (1992) · Nature · doi:10.1038/358581a0 · Cited by 426
Self-citationPathogenesis of cystic fibrosis
Koch, C., & Høiby, N. (1993) · The Lancet · doi:10.1016/0140-6736(93)92422-p · Cited by 426
Moss, R. B., Rodman, D., Spencer, L. T., Aitken, M. L., Zeitlin, P. L., Waltz, D., Milla, C., Brody, A. S., Clancy, J. P., Ramsey, B., et al. (2004) · Chest · doi:10.1378/chest.125.2.509 · Cited by 390
Self-citationClinical gene therapy using recombinant adeno-associated virus vectors
Mueller, C., & Flotte, T. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.68 · Cited by 313
Wagner, J. A., Nepomuceno, I. B., Messner, A. H., Moran, M. L., Batson, E. P., Dimiceli, S., Brown, B. W., Desch, J. K., Norbash, A. M., Conrad, C. K., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128577 · Cited by 266
Self-citationFlotte, T. R., Zeitlin, P. L., Reynolds, T. C., Heald, A. E., Pedersen, P., Beck, S., Conrad, C. K., Brass-Ernst, L., Humphries, M., Sullivan, K., et al. (2003) · Human Gene Therapy · doi:10.1089/104303403322124792 · Cited by 246
Self-citation
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Ratjen, F., Bell, S. C., Rowe, S. M., Goss, C. H., Quittner, A. L., & Bush, A. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.10 · Cited by 546
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Viral Vectors for Gene Therapy: Translational and Clinical Outlook
Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104938 · Cited by 424
Nanotechnology approaches for inhalation treatment of lung diseases
Kuzmov, A., & Minko, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.024 · Cited by 352
Clinical gene therapy using recombinant adeno-associated virus vectors
Mueller, C., & Flotte, T. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.68 · Cited by 313
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis
Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.014 · Cited by 272
In utero CRISPR-mediated therapeutic editing of metabolic genes
Rossidis, A. C., Stratigis, J. D., Chadwick, A. C., Hartman, H. A., Ahn, N. J., Li, H., Singh, K., Coons, B. E., Li, L., Lv, W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0184-6 · Cited by 216
Mastorakos, P., da Silva, A. L., Chisholm, J., Song, E., Choi, W. K., Boyle, M. P., Morales, M. M., Hanes, J., & Suk, J. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502281112 · Cited by 210
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
Alton, E. W. F. W., Beekman, J. M., Boyd, A. C., Brand, J., Carlon, M. S., Connolly, M. M., Chan, M., Conlon, S., Davidson, H. E., Davies, J. C., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208406 · Cited by 150
Guan, S., Munder, A., Hedtfeld, S., Braubach, P., Glage, S., Zhang, L., Lienenklaus, S., Schultze, A., Hasenpusch, G., Garrels, W., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0358-x · Cited by 130
Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing
Maule, G., Casini, A., Montagna, C., Ramalho, A. S., De Boeck, K., Debyser, Z., Carlon, M. S., Petris, G., & Cereseto, A. (2019) · Nature Communications · doi:10.1038/s41467-019-11454-9 · Cited by 86
Vidović, D., Carlon, M. S., da Cunha, M. F., Dekkers, J. F., Hollenhorst, M. I., Bijvelds, M. J. C., Ramalho, A. S., Van den Haute, C., Ferrante, M., Baekelandt, V., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0914oc · Cited by 74
Barker, S. E., Broderick, C. A., Robbie, S. J., Duran, Y., Natkunarajah, M., Buch, P., Balaggan, K. S., MacLaren, R. E., Bainbridge, J. W. B., Smith, A. J., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1327 · Cited by 59
Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease
Marquez Loza, L. I., Yuen, E. C., & McCray, P. B. (2019) · Genes · doi:10.3390/genes10030218 · Cited by 59
The Future of In Utero Gene Therapy
Peranteau, W. H., & Flake, A. W. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00445-y · Cited by 47
Genome-wide RNAi screening identifies host restriction factors critical for in vivo AAV transduction
Mano, M., Ippodrino, R., Zentilin, L., Zacchigna, S., & Giacca, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503607112 · Cited by 39
Genetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Tang, Y., Yan, Z., Lin, S., Huntemann, E. D., Feng, Z., Park, S.-Y., Sun, X., Yuen, E., & Engelhardt, J. F. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.008 · Cited by 21
Carlon, M. S., Vidović, D., Dooley, J., da Cunha, M. M., Maris, M., Lampi, Y., Toelen, J., Van den Haute, C., Baekelandt, V., Deprest, J., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.196 · Cited by 19
(2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000089 · Cited by 5
Metadata
- Authors
- Moss, R. B., Milla, C., Colombo, J., Accurso, F., Zeitlin, P. L., Clancy, J. P., Spencer, L. T., Pilewski, J., Waltz, D. A., Dorkin, H. L., Ferkol, T., Pian, M., Ramsey, B., Carter, B. J., Martin, D. B., & Heald, A. E.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2007-08
- Volume
- 18
- Issue
- 8
- Pages
- 726-732
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2061752094
- Cited by
- 277
- References
- 34
- FWCI
- 13.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.